Predictive Oncology Inc. (formerly Precision Therapeutics Inc.), of Minneapolis, which applies artificial intelligence to personalized medicine and drug discovery, priced a public offering of approximately 6.3 million common shares on a best efforts basis at 50 cents apiece for expected gross proceeds of up to $3.2 million.